NCT04832776 is a Phase 2 clinical trial of Cetuximab in Liver Metastasis Colon Cancer, sponsored by Fudan University.

Who is sponsoring NCT04832776?

NCT04832776 is sponsored by Fudan University.

What drugs are being tested in NCT04832776?

Interventions in NCT04832776: Cetuximab, Bevacizumab, FOLFOXIRI.

What condition does NCT04832776 study?

NCT04832776 studies Liver Metastasis Colon Cancer.

Is NCT04832776 still recruiting?

NCT04832776 is currently status unknown. Last updated 6 April 2021.

Last reviewed 2021-04-06 · How we verify

NCT04832776

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Status unknown Phase 2 Last updated 6 April 2021

What this trial tests

Phase 2 trial testing Cetuximab in Liver Metastasis Colon Cancer in 160 participants. Status unknown.

Timeline

17 April 2021

Primary endpoint
31 December 2023

31 December 2025

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	17 April 2021
Primary completion	31 December 2023
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Cetuximab (cetuximab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
FOLFOXIRI — full drug profile →

Conditions studied

Liver Metastasis Colon Cancer — all drugs for Liver Metastasis Colon Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Liver Metastasis Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cetuximab

Trials testing the same drug.

NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT06418724 — Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT07411599 — Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out · Phase 1, PHASE2 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting

Other recruiting trials for Liver Metastasis Colon Cancer

Currently open trials in the same condition.

NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo · NA · recruiting
NCT06185556 — COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Per · Phase 2, PHASE3 · recruiting
NCT06630624 — Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM · Phase 1, PHASE2 · recruiting
NCT05775146 — SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases · Phase 2 · recruiting
NCT06200831 — Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases · NA · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04832776 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 6 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04832776.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing